• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

1.170 -0.180 (-13.33%)
Streaming Delayed Price Updated: 2:54 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Propanc Biopharma, Inc. - Common Stock

< Previous 1 2 Next >
Friday's session: top gainers and losers ↗
August 28, 2026
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-08-27: top gainers and losers in today's session. ↗
August 27, 2026
Via Chartmill
These stocks are the most active in today's session ↗
August 27, 2026
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
August 27, 2026
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock... 
Via Benzinga
These stocks are moving in today's session ↗
August 27, 2026
Via Chartmill
News headline image
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
August 27, 2026
Differentiated Profile versus RAS-Targeted Approaches Including Revolution Medicines’ Daraxonrasib 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
August 18, 2026
Avance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
August 12, 2026
Contrasting Science with Revolution Medicines and Erasca 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
August 06, 2026
Accelerates Phase 1b First-in-Human Trial Timeline 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
August 05, 2026
Purchasing $500,000 within First 30 days Since Program Commencement 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
July 21, 2026
A Promising Strategy for Improving Production for Applications in Biotechnology Research 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
July 07, 2026
Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRP 
From Propanc Biopharma, Inc.
Via GlobeNewswire
Thursday's session: gap up and gap down stocks ↗
July 02, 2026
Via Chartmill
News headline image
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
July 02, 2026
The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
June 16, 2026
Pre-production, Engineering Run and GMP Manufacture of PRP in 2026 
From Propanc Biopharma, Inc.
Via GlobeNewswire
These stocks that are showing activity before the opening bell on Friday. ↗
June 12, 2026
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. ↗
June 11, 2026
Via Chartmill
These stocks are the most active in today's session ↗
June 11, 2026
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
June 11, 2026
Via Chartmill
News headline image
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
June 11, 2026
Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
June 02, 2026
Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing 
From Propanc Biopharma, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday? ↗
May 26, 2026
Via Chartmill
News headline image
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
May 20, 2026
Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
May 19, 2026
Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
May 15, 2026
Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
May 13, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
April 17, 2026
From Rosen Law Firm
Via Business Wire
These stocks are moving in today's after hours session ↗
April 17, 2026
Via Chartmill
News headline image
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
April 16, 2026
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
March 24, 2026
Fifth Agreement between Propanc & the Universities over a 17yr Period 
From Propanc Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap